AVIEW LCS vs Zio AT ECG Monitoring System
AI Verdict
Choose AVIEW LCS if…
Choose AVIEW LCS if your primary need is an AI-driven solution for comprehensive lung cancer screening and cardiopulmonary assessment from low-dose CT scans. This tool is ideal for radiology departments and pulmonology clinics seeking automated detection and analysis of lung nodules, emphysema, and coronary artery calcification, along with streamlined reporting and follow-up capabilities.
View AVIEW LCS →Choose Zio AT ECG Monitoring System if…
Choose Zio AT ECG Monitoring System if you require a wearable, long-term continuous ECG monitoring solution for the detection of cardiac arrhythmias. This system is best suited for cardiologists and clinicians needing to capture intermittent or asymptomatic cardiac events over an extended period (up to 14 days) with real-time data transmission and AI-powered analysis.
View Zio AT ECG Monitoring System →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | AVIEW LCS | Zio AT ECG Monitoring System |
|---|---|---|
| Pricing | Subscription or one-off payment | Contact for pricing |
| Deployment | Cloud-based, Hybrid solution, Locally on dedicated hardware, Locally virtualized (virtual machine, Docker) | Cloud-based (data analytics and clinician portal) |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Zio AT ECG Monitoring SystemTool B (Zio AT) offers a comprehensive user experience for both patients and clinicians, featuring a comfortable, water-resistant wearable patch for continuous monitoring and dedicated mobile apps for symptom logging and report interpretation. This patient-centric design, allowing for normal daily activities, broadens its usability beyond just clinical workflows.
Clinical Value
AVIEW LCSTool A (AVIEW LCS) provides a multi-faceted AI-powered assessment from a single low-dose CT scan, covering lung nodules, COPD, and coronary artery calcification. This comprehensive diagnostic scope, backed by FDA clearance and studies demonstrating high detection rates and reduced false positives, offers broad clinical value for early detection and risk stratification across multiple critical conditions.
Pricing & Value
Zio AT ECG Monitoring SystemBoth tools require direct contact for pricing, indicating a lack of public transparency. However, Tool B (Zio AT) provides more detail on its pricing model, explicitly mentioning service fees for monitoring and analysis, and offering financial assistance programs, self-pay options, and installment plans, along with broad insurance coverage. This transparency in financial support and coverage options adds to its perceived value and accessibility for patients.
Enterprise Readiness
AVIEW LCSTool A (AVIEW LCS) offers superior deployment flexibility, supporting cloud-based, hybrid, on-premise, and virtualized solutions, which caters to diverse enterprise IT infrastructures and security needs. Its explicit integration capabilities with existing PACS/RIS systems further ensure seamless adoption within large healthcare organizations.
Innovation
Zio AT ECG Monitoring SystemWhile both are innovative, Tool B (Zio AT) demonstrates a more disruptive innovation through its wearable, long-term (up to 14 days), continuous ECG monitoring with real-time data transmission and an FDA-cleared deep-learned AI algorithm. This approach significantly advances remote cardiac diagnostics by shifting from episodic to continuous, patient-friendly surveillance for often elusive arrhythmias.
Support & Docs
Zio AT ECG Monitoring SystemTool B (Zio AT) provides more explicit and comprehensive support resources, including dedicated customer care lines for patients and healthcare providers, clinical reference manuals, patient education materials via the MyZio app, and a redesigned help center. This breadth of accessible support and documentation is more robust than what is explicitly detailed for Tool A.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | AVIEW LCS | Zio AT ECG Monitoring System |
|---|---|---|
| Primary Focus | AI-powered solution for the detection and analysis of lung nodules, lung cancer, COPD, and coronary artery calcification from a single low-dose CT scan. | FDA-cleared, wearable mobile cardiac telemetry (MCT) service offering continuous, AI-powered ECG monitoring for long-term arrhythmia detection. |
| Company | Coreline Soft Co. | iRhythm Technologies, Inc. |
| Key AI-Powered Functionality | Automated lung nodule detection and analysis, Lung-RADS classification, Nodule volume quantification and 3D segmentation, Emphysema quantification (LAA index), Coronary Artery Calcification (CAC) scoring, Automated comparison of nodules in follow-up CT scans. | FDA-cleared deep-learned AI algorithm (ZEUS System) for arrhythmia detection. |
| Target Conditions/Diseases | Lung nodules, lung cancer, COPD, coronary artery calcification. | Arrhythmia (symptomatic and asymptomatic cardiac events). |
| Medical Specialties | Cardiology, Oncology, Pulmonology, Radiology | Cardiology |
| Reporting Capabilities | Comprehensive, automated report generation, Lung-RADS classification and reporting. | Comprehensive end-of-wear reports for clinicians, ZioSuiteu00ae clinician portal for report interpretation. |
Videos
Demos, reviews, and walkthroughs featuring AVIEW LCS and Zio AT ECG Monitoring System.
Frequently Asked Questions
More Comparisons
More matchups featuring AVIEW LCS or Zio AT ECG Monitoring System
Backers
Who funded each tool's parent company.